Evidence map›Paper›PMID 41069689›Full record

ReviewMaterials today. Bio2025

Cell membrane biomimetic nanoplatforms: a new strategy for immune escape and precision targeted therapy.

Jian Feng, Dixin He, Jingxia Chen, Mucong Li, Jiaxin Luo, Yuzhu Han, Xuyan Wei, Sicong Ren, Zhibo Wang, Yunxiao Wu and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jian FengJilin Provincial Key Laboratory of Science and Technology for Stomatology Nanoengineering, China.
Dixin HeJilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, China.
Jingxia ChenJilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, China.
Mucong LiJilin Provincial Key Laboratory of Science and Technology for Stomatology Nanoengineering, China.
Jiaxin LuoJilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, China.
Yuzhu HanJilin Provincial Key Laboratory of Science and Technology for Stomatology Nanoengineering, China.
Xuyan WeiJilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, China.
Sicong RenJilin Provincial Key Laboratory of Science and Technology for Stomatology Nanoengineering, China.
Zhibo WangJilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, China.
Yunxiao WuJilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, China.
Hanchi WangJilin Provincial Key Laboratory of Science and Technology for Stomatology Nanoengineering, China.
Yidi ZhangJilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, China.
Yanmin ZhouJilin Provincial Key Laboratory of Science and Technology for Stomatology Nanoengineering, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell membrane biomimetic nanoplatforms represent an innovative approach to addressing key challenges in nanodrug delivery systems by encapsulating natural cell membranes onto nanomaterials. This strategy confers unique biological properties that overcome immune clearance, extend in vivo circulation time, and enhance targeting specificity. This review systematically examines the construction strategies of these nanoplatforms and provides an in-depth analysis of immune escape mechanisms across different membrane sources-including erythrocyte, leukocyte, platelet, and tumor cell membranes-and their applications in precision-targeted therapies. We comprehensively explore cell membrane extraction and purification methods, nanocarrier selection, functionalization strategies, and membrane-nanocarrier integration techniques. The therapeutic applications of these platforms are examined across tumor treatment, inflammatory conditions, neurological disorders, and infectious diseases. Despite their significant clinical potential, challenges remain in large-scale production, standardized preparation protocols, and long-term safety assessment. This review also discusses future directions, including smart-responsive nanoplatform development, novel membrane source exploration, and multifunctionalization strategies, providing a theoretical foundation and technical reference for clinical translation of cell membrane biomimetic nanoplatforms.

Indexed as

Cell membrane bionanotechnologyClinical translationImmune escapeNanodrug deliveryNanomedicinePrecision targeted therapy

Identifiers

PMID41069689
PMCPMC12506577

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.